tenofovir alafenamide

This page shows the latest tenofovir alafenamide news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy

Latest news

GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
Gilead’s Biktarvy gets European approval, setting up battle with GSK

The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).
The year of the blockbuster

Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

However Gilead has its own direct competitor, Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's Descovy, a combo of emtricitabine and tenofovir alafenamide.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There was also good news at the CHMP meeting for Gilead Sciences’HIV division, with the panel giving its blessing to three-drug, fixed-dose therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

More from news
Approximately 4 fully matching, plus 31 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Graduate Scientific Editor: DOE

Medical Writer - Creative and Scientific Projects: DOE

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Account Manager- 4 days per week or full-time: Salary TBC

Senior Writer, Healthcare Advertising, London: Excellent package

Medical Writers Required - Hertfordshire: Competitive

Market Access Consultant - Greater Manchester: Negotiable

Healthcare PR Director: £100, 000 – £120, 000 benefits

Sudler London - Senior Medical Writer: Competitive

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Senior Medical Writer: Salary is DOE

Healthcare PR Senior Account Manager: Salary TBC

Account Manager: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Subscribe to our email news alerts

PMHub

Add my company

Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....